ev3 — Q4 2009 Earnings Presentation
18 slides from ev3's earnings presentation, Feb 18, 2010
Slide 1: Q4 '09 Highlights
Q4 '09 Highlights February 18, 2010
Slide 2: Forward-Looking Statements
Forward-Looking Statements Statements contained in this presentation that relate to future, not past, events are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Forward-looking statements often can be identified by words such as "expect," "anticipate," "intend,
Slide 3: Use of Non-GAAP Financial Measures
Use of Non-GAAP Financial Measures ev3 uses certain non-GAAP financial measures in this presentation. ev3 uses non-GAAP financial measures as supplemental measures of performance and believes these measures provide useful information to investors in evaluating our operations, period over period. How
Slide 4: Q4 '09 Financial Summary
Q4 '09 Financial Summary Net product sales of $126.8 million +20% vs. Q4 2008; +16% constant currency* Peripheral vascular sales +8% vs. Q4 2008; +6% constant currency* Plaque excision +19% vs. Q4 2008, +18% constant currency* Peripheral stents -3% vs. Q4 2008; -6% constant currency* Thrombectomy an
Slide 5: Q4 '09 Operational Highlights - Peripheral Vascular
Q4 '09 Operational Highlights - - Peripheral Vascular TurboHawk(tm) Plaque Excision System launched in U.S. for endovascular use Incremental opportunity to treat calcified above-the-knee lesions New 'Super Cutter' blade, jog and drive shaft combine to remove more plaque per pass TurboHawk added to D
Slide 6: Q4 '09 Operational Highlights - Neurovascular
Q4 '09 Operational Highlights - - Neurovascular International launch for Pipeline(tm) Embolization Device (PED) progressing very well Now have approx. 80 physicians who are fully certified or who have nearly completed training & certification process AXIUM(tm) MicroFx PGLA & Nylon coils physician pr
Slide 7: Actual Results vs. Last Quarter & Year Ago
Actual Results vs. Last Quarter & Year Ago * Constant Currency; For reconciliations, see our website at www.ev3.net. ** All quarters presented are adjusted for amortization and non-cash stock-based compensation. Q2 2009 is also adjusted for a non-cash tax benefit resulting from the acquisition of Ch
Slide 8: Total Q4 '09 Product Revenue Growth of 16%*
Total Q4 '09 Product Revenue Growth of 16%* Q1 Q2 Q3 Q4 Q4 East 100.4 109.1 112.8 105.6 126.8 Q1 Q2 Q3 Q4 Q4 East 38.7 41.4 44.4 39.4 53.6 Total International ($M) +26%* Q1 Q2 Q3 Q4 Q4 East 66.2 72 67.6 68.1 73.7 Worldwide Peripheral Vascular ($M) +6%* Q1 Q2 Q3 Q4 Q4 East 34.2 37.1 45.2 37.5 53 Worl
Slide 9: Key 2009 Financial Indicators
Key 2009 Financial Indicators $M Adj. Operating Margin1 Product Sales Adjusted EPS2 Cash Flow from Operations $ SG&A as % of net sales 55% 50% 49% 1. Excludes non-cash FoxHollow lease reserve adjustment in Q1 2009. For reconciliations of Adjusted Operating Margin, see our website at www.ev3.net. 2.
Slide 10: Balance Sheet is Strengthening - We are Generating Cash
Balance Sheet is Strengthening - - We are Generating Cash Cash / Cash Equivalents Cash flow from operating activities totaled $22.0M in Q4 '09 Cash/cash equivalents increased $17.5M in Q4 '09 vs Q3 '09 Inventory days increased 6% in Q4 '09 vs Q4 '08 Total debt decreased to $6.5M Q4 08 Q1 09 Q2 09 Q3
Slide 11: Improving Cost Structure - Continuing Progress
Improving Cost Structure - Continuing Progress Q4 08 Q4 09 East 0.672 0.759 Gross Margin % of sales SG&A % of sales Q4 08 Q4 09 East 0.5 0.47 Favorable product mix, improved yields and labor efficiency, higher volumes Continued focus on leveraging cost structure and improving margins
Slide 12: Annualized Net Sales Per Territory
Annualized Net Sales Per Territory Q4'09 up 27% vs. Q4'08 Key Drivers Plaque Excision Clinical Specialists Corporate Account penetration Market development DEFINITIVE clinical data Neuro business already > $2M per territory Increasing Peripheral Vascular Sales Force Productivity in U.S. Q4 08 Q1 09
Slide 13: Financial Summary: Continuing to Improve Performance
Financial Summary: Continuing to Improve Performance Net Product Sales* $126,753 $105,656 $100,395 $109,086 $112,838 Gross Profit $96,214 $71,316 $69,407 $78,608 $84,230 Gross Margin 75.9% 67.2% 69.1% 72.1% 74.6% Net Income (loss) $13,001 $(291,120) $(1,809) $23,989 $6,736 Adjusted EPS per diluted s
Slide 14: Guidance - As of February 18, 2010
Guidance - As of February 18, 2010 Full-Year 2010 Guidance Revenues: Q1 2010: $115 to $118 million Full-Year 2010: $500 to $515 million Adjusted EPS1 per diluted share: Q1 2010: $0.12 to $0.151,2 Full-Year 2010: $0.78 to $0.841,2 Adjusted EPS guidance is based on weighted average diluted shares outs
Slide 15: Business Model Structure - Select P&L Information
2008 % of sales 2007 2010 Goal Business Model Structure - - Select P&L Information Sales 100% 100% 100% Gross margin 66% 65% 73% Selling, general & administrative* 55% 69% 50% Research & development 12% 17% 11% Stock-based comp, amortization & contingent consideration 11% 11% 10% Adjusted net income
Slide 16: Key Growth Drivers
Key Growth Drivers Long growth runway 3. Next gen plaque excision 1. Commercial execution 2. Flow diversion 5. International 6. Clinical studies 7. Selective M&A 4. Ischemic stroke
Slide 17: In Summary: Why Invest in ev3
IN SUMMARY: WHY INVEST IN ev3 ev3: Leading the Way Investing in 8 clinical studies to expand usage Powerful Growth Drivers Robust pipeline of novel products - 20 launches by 2012 Leveraging business model improving gross margin expanding operating income Pipeline(tm) - a game changing product Profit
Slide 18: www.ev3.net Contact Info
NASDAQ: EVVV www.ev3.net Contact Info: Julie Tracy - Sr. VP, Chief Communications Officer (949) 680-1375 [email protected]